"Our results show that, at a population level, prescriptions of stimulants and antidepressant medications for children and adolescents do not appear to be prescribed at rates higher than the known rates for psychiatric conditions they are designed to treat," said the study's lead author, Dr. Ryan Sultan.
Findings from a new Cochrane Review caution clinicians to weigh the benefits and risks more carefully when prescribing methylphenidate.
Impax announced that the Food and Drug Administration (FDA) has approved Guanfacine Extended-Release Tablets, the generic version of Shire's Intuniv.
Tris Pharma announced that the FDA has approved Dyanavel XR (amphetamine) extended-release oral suspension for the treatment of attention deficit hyperactivity disorder (ADHD) in children aged ≥6 years.
In the first multi-state report from the Centers for Disease Control and Prevention (CDC)'s Prescription Behavior Surveillance System (PBSS), state prescribing practices for prescription opioid pain relievers, benzodiazepines (sedatives/tranquilizers), and stimulants vary significantly despite a similar prevalence of the conditions these medications are intended to treat.
Researchers from Cincinnati Children's Hospital Medical Center have found no increased mortality or changes in cardiac vital signs among children with congenital heart disease taking attention-deficit/hyperactivity disorder (ADHD) stimulant medications. The study results will be presented at the annual meeting of the Society for Developmental and Behavioral Pediatrics in Las Vegas.
An initial attention-deficit/hyperactivity disorder (ADHD) diagnosis may be associated with delayed autism spectrum disorder (ASD) diagnosis.
Almost a third of U.S. children with attention-deficit/hyperactivity disorder (ADHD) were diagnosed before the age of 6, even though there aren't many valid tests to support diagnosis in children that young.
Risks of attention-deficit/ hyperactivity disorder (ADHD) are greatest for children with the most severe degree of poor growth in the womb, according to research published in Pediatrics.
After 28 days of citicoline supplementation, adolescent males showed statistically significant increased motor speed, improved attention, and decreased impulsivity in research published in the Journal of Attention Disorders.
The New Drug Application (NDA) for NT-0202 (amphetamine XR-ODT, Neos) has been resubmitted to the Food and Drug Administration (FDA) for the treatment of attention-deficit/hyperactivity disorder (ADHD).
Children with attention-deficit/hyperactivity disorder (ADHD) undergoing sedation for magnetic resonance imaging (MRI) do not have a higher dose requirement for propofol.
New research in JAMA Psychiatry reports that use of antipsychotics increased among adolescents and young adults over a four-year period, even though more than half did not have an outpatient or inpatient claim that included a mental disorder diagnosis.
Evekeo (amphetamine sulfate; Arbor) tablets administered once or twice daily to children aged 6 to 12 years was effective in treating attention deficit hyperactivity disorder (ADHD) symptoms and improving performance in a laboratory classroom setting, reports a new study.
The Food and Drug Administration (FDA) has issued a warning that the use of Daytrana patch (methylphenidate transdermal system; Noven) may result in permanent loss of skin color.
Evekeo (amphetamine sulfate; Arbor) tablets are available for the treatment of attention deficit hyperactivity disorder (ADHD) as part of a total treatment program in patients aged 3 years and older.
Teva announced the launch of Dexmethylphenidate HCl Extended-Release Capsules in a new 20mg strength, the generic of Novartis' Focalin XR.
A drug indicated for the treatment of attention deficit hyperactivity disorder (ADHD) and binge eating disorder also helped women with executive functions related to menopause in research appearing in the journal Psychopharmacology.
A new algorithm developed by scientists at Columbia University Medical Center (CUMC) supports previously reported associations between a person's birth month and overall disease risk, including 16 new links that include nine types of heart disease.
Trends in use of psychotropic medication in children and adolescents with Down syndrome (DS) appear to be age-related, as a new study in the Journal of Developmental & Behavioral Pediatrics suggests that teens and young adults are significantly more likely to be on psychotropic medications compared to younger children.
Sandoz, Teva, and TWi Pharmaceuticals announced the launch of Guanfacine HCl Extended-Release Tablets, the generic version of Shire's Intuniv.